Research Pipeline
Status of major offerings in Genmab's research pipeline, as of September 2010.
| Product | Disease Indications | Phase | Partner |
|---|---|---|---|
| Ofatumumab (20 Studies) | Chronic lymphocytic leukemia (CLL) | III | GSK |
| Ofatumumab | Non-Hodgkin’s Lymphoma (NHL) | III | GSK |
| Ofatumumab | Rheumatoid arthritis (RA) | III | GSK |
| Ofatumumab | Diffuse Large B-cell Lymphoma (DLBCL) | III | GSK |
| Ofatumumab | Relapsing Remitting Multiple Sclerosis (RRMS) | II | GSK |
| Ofatumumab | Waldenstrom’s Macroglobulinemia (WM) | II | GSK |
| Zalutumumab (6 studies) | Head & Neck Cancer | III | - |
| Daratumumab | Multiple Myeloma | I/II | - |
| RG4930 | Asthma - Target: Ox40L | I | Roche |
| RG1512 | Peripheral vascular disease - Target: P-selectin | I | Roche |
| HuMax-cMet | Cancer | Pre-clinical | - |
| HuMax-TF | Cancer | Pre-clinical | Seattle Genetics |
| HuMax-Her2 | Cancer | Pre-clinical | - |
Read more about this topic: Genmab
Famous quotes containing the words research and/or pipeline:
“To be sure, nothing is more important to the integrity of the universities ... than a rigorously enforced divorce from war- oriented research and all connected enterprises.”
—Hannah Arendt (1906–1975)
“Even in the pink crib
the somehow deficient,
the somehow maimed,
are thought to have
a special pipeline to the mystical....”
—Anne Sexton (1928–1974)